Department of Molecular Genetics, Madras Diabetes Research Foundation, ICMR Advanced Centre for Genomics of Type 2 Diabetes and Dr. Mohan's Diabetes Specialties Centre, WHO Collaborating Centre for Non-Communicable Diseases Prevention & Control, IDF Centre of Education, Chennai, India.
Department of Biochemistry and Molecular Biology, Oregon Health and Science University, Portland, Oregon.
Pediatr Diabetes. 2019 Jun;20(4):397-407. doi: 10.1111/pedi.12843. Epub 2019 Apr 2.
Gain-of-function of ATP-sensitive K (K ) channels because of mutations in the genes encoding SUR1 (ABCC8) or Kir6.2 (KCNJ11) is a major cause of neonatal diabetes mellitus (NDM). Our aim is to determine molecular defects in K channels caused by ABCC8 mutations in Asian Indian children with NDM by in vitro functional studies.
Wild-type (WT; NM_000352.4) or mutant sulfonylurea receptor 1 (SUR1) and Kir6.2 were co-expressed in COSm6 cells. Biogenesis efficiency and surface expression of mutant channels were assessed by immunoblotting and immunostaining. The response of mutant channels to cytoplasmic ATP and ADP was assessed by inside-out patch-clamp recordings. The response of mutant channels to known K inhibitors in intact cells were determined by Rb efflux assays.
Five SUR1 missense mutations, D212Y, P254S, R653Q, R992C, and Q1224H, were studied and showed increased activity in MgATP/MgADP. Two of the mutants, D212Y and P254S, also showed reduced response to ATP inhibition, as well as markedly reduced surface expression. Moreover, all five mutants were inhibited by the K channel inhibitors glibenclamide and carbamazepine.
The study shows the mechanisms by which five SUR1 mutations identified in Asian Indian NDM patients affect K channel function to cause the disease. The reduced ATP sensitivity caused by the D212Y and P254S mutations in the L0 of SUR1 provides novel insight into the role of L0 in channel inhibition by ATP. The results also explain why sulfonylurea therapy is effective in two patients and inform how it should be effective for the other three patients.
由于编码 SUR1(ABCC8)或 Kir6.2(KCNJ11)的基因突变导致 ATP 敏感性钾(K )通道功能获得,是新生儿糖尿病(NDM)的主要原因。我们的目的是通过体外功能研究,确定亚洲印度 NDM 儿童 ABCC8 突变引起的 K 通道的分子缺陷。
野生型(WT;NM_000352.4)或突变磺酰脲受体 1(SUR1)和 Kir6.2 在 COSm6 细胞中共同表达。通过免疫印迹和免疫染色评估突变通道的生物发生效率和表面表达。通过内向外膜片钳记录评估突变通道对细胞质 ATP 和 ADP 的反应。通过 Rb 外排测定确定突变通道对已知 K 抑制剂在完整细胞中的反应。
研究了 5 种 SUR1 错义突变,D212Y、P254S、R653Q、R992C 和 Q1224H,发现它们在 MgATP/MgADP 中活性增加。两种突变体,D212Y 和 P254S,也显示出对 ATP 抑制的反应降低,以及表面表达明显减少。此外,所有 5 种突变体均被 K 通道抑制剂格列本脲和卡马西平抑制。
该研究表明,在亚洲印度 NDM 患者中发现的 5 种 SUR1 突变影响 K 通道功能导致疾病的机制。SUR1 的 L0 中的 D212Y 和 P254S 突变导致的 ATP 敏感性降低,为 L0 在 ATP 抑制通道中的作用提供了新的见解。结果还解释了为什么磺酰脲治疗对 2 名患者有效,并说明了它应该如何对其他 3 名患者有效。